Lowest Price Guaranteed
Pages
356
Last Updated
December 2025
View Count
21373
The single use bioreactors market, valued at USD 4.32 billion in 2025, is projected to reach USD 4.81 billion in 2026 and USD 10.48 billion by 2035, with a CAGR of 9.03% during the forecast period, 2026 to 2035.
 |
To learn more about this report, request a free sample copy
Single-use bioreactor, also known as disposable bioreactor, employs single use bioreactor bags instead of stainless-steel culture vessel for the manufacturing of various biologic. These bioreactors offer various advantages over conventional bioreactors, such as cost efficiency (~40%), shorter production timeline (~35%), reduction in energy and water consumption (45%-50%), better product yield and low risk of contamination.
 |
 |
 |
Over the past few years, biopharmaceuticals have gained significant attention; over 170 biologics have received the US FDA approval, while over 10,000 biologics are currently under different stages of development. To fulfill the growing demand for biologics, such as high quality antibodies, cell therapies, gene therapy, a gradual shift towards the use of a single use bioreactor has been observed.
 |
 |
 |
Many single use bioreactor manufacturers are focusing on incorporating a variety of advanced features, including provisions for alerts / alarms, electronic process logs, built-in system process control sensors, touch screens, remote monitoring features, and advanced safety provisions in their offerings to develop more efficient bioreactors for global markets.
 |
 |
 |
| Key Report Attributes | Details | |
| Historical Trend | Since 2022 | |
| Forecast Period | Till 2035 | |
| Market Size 2026 | $4.81 Billion | |
| Market Size 2035 | $10.48 Billion | |
| CAGR | 9.03% | |
The single use bioreactor market analysis also features the likely distribution of the current and forecasted opportunity across various segments, such as type of bioreactor, scale of operation, type of cell culture, type of biologics synthesized, end users and geographical regions.
In order to account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of single use bioreactors market growth.
The ongoing technological advancements focused on the development of improved versions of biosensors and single use bioreactor bags are likely to encourage the biopharmaceutical companies to adopt disposable bioreactors for continuous bioprocessing, representing a lucrative opportunity for companies engaged in this growing market.
Several recent developments have occurred in the field of single use bioreactors, and we outline some of these below. These developments, even if they arose after our market report’s release, support the overall single use bioreactors market trends detailed in our analysis.
The single use bioreactors market report presents an in-depth analysis of the various single use bioreactor manufacturers, across different segments, as defined in the table below:
| Market Segmentations | Details | |
| Type of Bioreactor |
|
|
| Scale of Operation |
|
|
| Type of Cell Culture |
|
|
| Type of Biologics Synthesized |
|
|
| End Users |
|
|
| Geographical Regions |
|
|
Given the bioreactor manufacturers are continuously putting efforts into improving their product portfolio for addressing the challenges related to biomanufacturing by delivering innovative disposable bioreactors to the pharmaceutical industry, the demand for such solutions is likely to increase in the future.
Discussions with multiple stakeholders in this domain influenced the opinions and insights presented in this study. The market report includes detailed transcripts of interviews conducted with the following individuals:
Single Use Bioreactors domain will mark a turning point in 2026. Jean-Marc Cappia (Head of Market Development Intensified Chromatography, Sartorius Stedim Biotech), states, “The main challenge for our industry is making more drugs available and affordable because millions of children are still dying of infectious diseases for which vaccines exist. Single-use technology and process intensification are ways of addressing these challenges. Introduction of single-use equipment will continue to grow because the era of large blockbusters is behind us.”
| Report Deliverables | Details | |
| Excel Data Packs (Complimentary) |
|
|
| Key Single Use Bioreactor Manufacturers |
|
|
| PowerPoint Presentation (Complimentary) |
Available | |
| Customization Scope | 10% Free Customization | |
The “Single Use Bioreactors Market (4th Edition): Industry Trends and Global Forecasts, till 2035” report features an extensive study of the current market landscape, market size and future opportunities associated with this industry, for the given forecast period. The market research report highlights the efforts of single use bioreactor manufacturers engaged in this emerging and rapidly evolving segment of the bioprocessing industry.
The growing demand for quality products has encouraged biologic manufacturers to adopt single-use bioreactors, a more advanced and long-term solution. These disposable bioreactors are cost effective and have the capability to provide operational flexibility as compared to stainless steel bioreactors, thereby propelling the biopharmaceutical companies to adopt disposable bioreactors for bioprocessing.
Other advantages of single use bioreactors over conventional stainless steel bioreactors include ~50% reduction in total energy and water consumption and ~40% cost saving by elimination of cleaning and sterilization processes after every batch production.
The current single use bioreactors manufacturers landscape features the presence of over 60 industry stakeholders developing more than 260 single-use bioreactors. The market is highly fragmented with the presence of large, mid-sized and small companies. It is worth highlighting that constant evolution of disposable bioreactors is likely to support the development of novel and more efficacious biologics, in turn, contributing to the substantial growth of single use bioreactors market, during the forecast period.
The global single use bioreactors market size is likely to be worth $ 4.81 billion in 2026 and will reach $ 10.48 billion by 2035. In terms of the type of bioreactor, stirred tank bioreactors segment dominates the single use bioreactors market share. The single use stirred tank bioreactor segment captures 80% of the market share and it is likely to grow at a CAGR of 14% during the forecast period. Single use stirred tank bioreactors gained attention during the COVID-19 pandemic in their role to meet the global demand for COVID vaccines and streamlining the manufacturing process at widespread manufacturing facilities.
The broader application areas of single use bioreactors and their easy installation and handling, along with their high productivity and efficiency, are the primary drivers of this market. Further, single-use bioreactors require less space than conventional systems and offer cost effectiveness for companies, thus it is likely to significantly drive the adoption of these solutions in the future.
Overall, the companies based in North America and Europe capture 75% share of the current market. Companies such as ABEC, Eppendorf, Merck Millipore, PBS Biotech and Thermo Fisher Scientific offer a wide range of single use bioreactors. These companies have in-house single use bioreactor portfolio, with different types of bioreactors, such as stirred tank bioreactor, wave / induced bioreactor and pneumatically mixed bioreactor. This is due to the presence of advanced biopharmaceutical industries, significant investments in biotechnology, robust research infrastructure, and strong regulatory support in developed regions.
Furthermore, the recent pressure from the Trump administration related to import tariffs is also driving the pharmaceutical and biotechnology companies to invest in manufacturing facilities in the US. A number of big pharmaceutical companies have already announced their investments in biologics manufacturing facilities in the US including Merck, AbbVie, Eli Lilly, Roche, Novartis and Johnson & Johnson. New facilities will drive the demand for single use bioreactors over the forecast period.
The market in Asia-Pacific is expected to grow at a relatively high CAGR (11%), during the forecast period till 2035. This is due to the establishment of several manufacturing facilities in Asia-Pacific region to meet the growing local demand for biologics from the consumers as well as the demand from small biopharmaceutical startups.
A number of manufacturing facilities are being set up in Asia Pacific region, to meet the growing local demand for biologics from the consumers. Moreover, a number of CMOs are setting up new facilities or announcing expansions in countries such as Singapore and Korea. WuXi Biologics is slated to open its 120,000 L capacity manufacturing facility at Tuas Biomedical Park, Singapore.
One of the key challenges faced by single use bioreactor manufacturers is the reluctance of industry players to adopt these novel systems. This is due to the expenses that they are likely to incur while switching to new technology. Further, disposable bioreactors pose a reasonable risk of contamination from extractables and leachables, which can jeopardize the safety of drug products and well-being of the patient. It is worth highlighting that several disposable bioreactor manufacturers are striving to tackle these challenges through innovation in design and manufacturing methods.
The current inability of single use bioreactors to operate at volume greater than 6,000 L for large scale production, remains another pressing concern. Furthermore, with the growing focus on sustainability goals, the plastic waste generated through the use of single use bioreactors is concerning to the manufacturers.
Single use bioreactor manufacturers have forged several partnerships with other stakeholders to consolidate their presence in this field and enhance their capabilities and product portfolio to meet the growing demand for biotherapeutics. In fact, the partnership activity in this domain grew at a CAGR of ~15% over the past five years. Interestingly, most of the agreements were supply and technology integration agreements. The domain also witnessed a significant number of mergers and acquisitions during the past five years, indicating the growing interest of stakeholders in this industry.
It is worth mentioning that ABEC, Henan Lanphan, and Thermo Fisher Scientific are amongst the key players that have launched the largest single-use bioreactors with a capacity of more than 4,000 L. A number of CDMOs are adoptinghave shown positive interest in the adoption of these large-scale bioreactors. In a recent announcement, AGC Biologics announced its plans to install two 5,000 L DynaDrive SUBs from Thermo Fisher at its Yokohama, Japan facility which is slated to begin operations in 2026. In April 2023, mAbxience, a Spanish CDMO installed a 4,000 L single-use bioreactor manufactured by ABEC, at its Leon facility. Earlier, in 2018, WuXi Biologics had also installed these 4,000 L bioreactors for large scale single use bioprocessing at their Wuxi city manufacturing facility.
Stakeholders engaged in this industry are identifying new ways to enhance efficiency and reduce turnaround time. This has led to various technological advancements in this field, which include alerts / alarms, built-in system process control sensors, electronic process logs, remote monitoring features, touch screens, and advanced safety provisions, that have demonstrated an increase in efficiency and quality of the process.
The single use bioreactors market is witnessing the adoption of bioprocessing 4.0 solutions that leverage machine learning (ML) and artificial intelligence (AI) for real-time process monitoring. These advancements are likely to result into better yields, reduced waste, and development of higher quality biologics.
The market report presents an in-depth analysis, highlighting the capabilities of various stakeholders in the single use bioreactors industry, across different geographies. Amongst other elements, the market report includes:
Single-use bioreactors utilize disposable plastic bags for culturing cells, offering reduced contamination risks and lower operational costs compared to traditional stainless-steel systems. Key drivers of this market include the growing demand for biologics, regulatory emphasis on flexible manufacturing, and the need for faster production cycles with minimum cross contamination risks. Single use bioreactors are becoming a mainstay in the bioprocessing industry, with the manufacturers trying to plug the gaps in the market through launch of large-scale single use bioreactors. As the technology for recycling plastic waste develops, their adoption will witness a positive push.
Lead Author: Akarshika Singh
Lead Reviewer: Dhriti Gulati
Chief Editor: Simriti Gupta